Ad
related to: mnkd share price history tsp newssuperstockscreener.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application ...
Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
After three quarters of positive earnings per share from Q3, 2023 through the first quarter of 2024 we had a net loss in the current quarter of $2 million, or $0.01 per share.
History [ edit ] Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
(For example, 500 shares at $32 may become 1000 shares at $16.) Many major firms like to keep their price in the $25 to $75 price range. A US share must be priced at $1 or more to be covered by NASDAQ. If the share price falls below that level, the stock is "delisted" and becomes an OTC (over the counter stock). A stock must have a price of $1 ...
MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ad
related to: mnkd share price history tsp newssuperstockscreener.com has been visited by 10K+ users in the past month